Abzu, member of CataloniaBio & HealthTech, announced the appointment of Victor Galindo, as its new Chief Executive Officer. Victor, a co-founder of Abzu and previously Abzu’s Chief Technology Officer, succeeds Casper Wilstrup, who has been steering the company since 2018.
Over the past 6.5 years at Abzu, Victor has been a key architect and engineer in developing Abzu’s proprietary, explainable AI, the QLattice®, and Abzu’s offerings in the design and delivery of RNA therapeutics. Victor has also been essential in applying the QLattice in disease understanding and drug design in new therapeutic modalities.
“I am honored to lead Abzu and build on the strong foundation laid down by Casper,” says Victor Galindo, “with an excellent track record in scientific citations and the achievements of our proprietary, explainable AI, I see a promising future for Abzu in all of life science. The QLattice is, at its core, an AI fit for science. And I look forward to bringing it to more scientists.”
“After over six incredible years filled with amazing highs and a few tough lows, I’m ready for a break. I’m proud to announce that my co-founder and CTO, Victor Galindo, will be stepping into the CEO role. I have complete confidence in his leadership and ability to take Abzu to the next level,” says Casper Wilstrup, former CEO of Abzu.
Related news:
Comments